Administration of gut-selective JAK3 inhibitor
US11471442B2 · kind B2 · utility
0Cited by
3References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 2021 |
| Grant date | Oct 18, 2022 |
| Priority date | — |
| Expiry date | May 13, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of safely administrating a gut-selective JAK3 inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of gastrointestinal inflammatory diseases, such as celiac disease, by oral administration of a gut-selective JAK3 inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.